Funding Announcements

"Difficulty taking tablets is a common problem in paediatrics but extends to adults experiencing swallow impairment, including those suffering from serious conditions such as stroke, dementia and some forms of cancer. Our liquid products are effective and stable at room temperature with a long shelf life, improving medication adherence, dosage accuracy and convenience for the NHS, patients, and caregivers. We are thrilled to receive this investment, which will help us make a significant impact on the global pharmaceutical landscape."

"When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could transform precision medicine. Since then, the team has consistently delivered. The immune system sits at the heart of almost every disease, and IMU’s ability to analyse it at this resolution could redefine how treatments are matched to patients. We’re proud to be IMU’s largest shareholder and excited to support the company’s next phase of growth."

"Decarbonising construction cannot come at the expense of cost or performance. The challenge has been scaling biomaterials industrially and integrating them into real construction supply chains."

"What I see right now is that the companies that will make a radical difference in this emerging AI-driven future are all AI-native, lean on real world data, have genuine impact, and are fundamentally deep tech. Imperagen has each of those characteristics, combining them with outstanding people, phenomenal technology and the undeniable swagger you only get from Manchester. It was a no-brainer to join the team and lead this next stage in its growth."